 Initiated Phase 1 Multiple Ascending Dose Clinical Trial of Fezagepras OXER1 Antagonist Preclinical RD Program Acquired Changes to Board of Directors Executive Team US30M in gross proceeds from a private placement closed in November C29.1M in proceeds from long-term loan from SALP in September Updated Business Strategy Focused on Small Molecule Therapeutics PDUFA Target Action Date of June 5, 2021 for Ryplazim plasminogen BLA Submission LAVAL, QC and CAMBRIDGE, England, March 24, 2021 PRNewswire - Liminal BioSciences Inc. Nasdaq: LMNL Liminal BioSciences or the Company, a clinical-stage biopharmaceutical company, today reported its financial results for the fourth quarter and year ended December 31, 2020. Liminal will host a conference call at 08:30am ET on Thursday March 25, 2021. 